News | Radiation Therapy | October 17, 2018

After successful validation of Dolphin interoperability, online patient dose measurements during actual treatment delivery will enable verification of the correctness of each treatment fraction

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

October 17, 2018 — IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the Dolphin transmission detector for online monitoring of patient treatment.

With the health, security and safety of patients in focus, modern radiation therapy has become highly specialized, which has led to different complex treatment techniques being developed and used daily in patient cancer therapy. This in turn requires new and comprehensive quality assurance (QA) solutions that address the growing number of possible sources and impact of dose deviations, in particular for high-dose cases.

For online patient plan monitoring, IBA Dosimetry is set to release the Dolphin online solution with its Compass 3D verification software, and has therefore entered into an interoperability agreement with Varian.

The Dolphin online functionality enables the measurement of each fraction dose and the verification of the actual radiation dose delivered to patients. The ability to measure treatment accuracy fraction by fraction will provide the confidence and safety needed to deliver the highest quality of care to the patient.

Dolphin includes the following five checks for verification of the complete treatment chain:

  • Real measurement of the plan delivery. In contrast to solutions that purely recalculate the patient plan via log files, the Dolphin advanced high-resolution ionization chamber detector array enables real measurements of each fraction dose and detection of errors in treatment delivery, such as beam line defects, multileaf collimator (MLC) deviations, dose rate changes, flatness/symmetry drifts, gantry positioning errors, etc.;
  • Verification of the real patient plan where no surrogate QA plan is required;
  • Secondary dose calculation with treatment planning system (TPS)-class algorithm. Secondary verification of the TPS dose calculation enables detection of errors in the TPS algorithm, TPS performance or in the TPS export;
  • Machine constancy checks with myQA. In addition, Dolphin’s detector array is optimized to find deviations and trends in linear accelerator (LINAC) constancy for profiles, output and wedge factors; and
  • Independent verification of the treatment planning system. The independent beam model of Dolphin’s verification software enables detection of errors in the TPS configuration and performance, its beam model, commissioning, or the LINAC calibration
     

Dolphin is currently in clinical use around the world for advanced measurement-based pre-treatment patient QA.

For more information: www.iba-dosimetry.com


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now